Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients

NCT06070272 | Not Yet Recruiting

• 1 other identifier: 72630763
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.

Conditions

Recurrent Prostate Cancer

Keywords

Recurrent Prostate Cancer

Outcome Measures

Primary Outcomes (2)

• Number of patients who decide to participate in a recurrent prostate cancer clinical research

  3 months

• Rate of patients who remain in recurrent prostate cancer clinical research to trial completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with recurrent prostate cancer who are actively considering enrolling in a clinical study, but have not yet completed enrollment and randomization.

You may qualify if:

• Patient is at least 18 years of age
• Diagnosis of recurrent prostate cancer
• Ability to understand and the willingness to sign a written informed consent document

You may not qualify if:

• Enrolled in another research study
• Patients with psychiatric illness/social situations that would limit compliance with study requirements
• Inability to provide written informed consent

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

Location

Related Publications (3)

• Hefermehl LJ, Disteldorf D, Lehmann K. Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study. BMJ Open. 2016 Feb 17;6(2):e010191. doi: 10.1136/bmjopen-2015-010191.

  PMID: 26888730 BACKGROUND

• Wollersheim BM, Helweg E, Tillier CN, van Muilekom HAM, de Blok W, van der Poel HG, van Asselt KM, Boekhout AH. The role of routine follow-up visits of prostate cancer survivors in addressing supportive care and information needs: a qualitative observational study. Support Care Cancer. 2021 Nov;29(11):6449-6457. doi: 10.1007/s00520-021-06222-9. Epub 2021 Apr 26.

  PMID: 33900459 BACKGROUND

• Ye D, Zhang W, Ma L, Du C, Xie L, Huang Y, Wei Q, Ye Z, Na Y. Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. Chin J Cancer Res. 2019 Jun;31(3):511-520. doi: 10.21147/j.issn.1000-9604.2019.03.13.

  PMID: 31354220 BACKGROUND

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2023
• First Posted: October 6, 2023
• Study Start: October 1, 2024
• Primary Completion: October 1, 2025
• Study Completion (Estimated): October 1, 2026
• Last Updated: October 6, 2023

Record last verified: 2023-09

Locations

US (1)